Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

SDMJ consulting

market access in Japan

Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

Petauri Evidence

- PMLiVE

Merck’s Keytruda gains two more approvals in Japan

New approvals in breast and colorectal cancer take the number of indication for the immunotherapy mega-blockbuster to 15 in Japan

AstraZeneca AZ

AstraZeneca’s Forxiga approved in Japan for the treatment of CKD

Approval was based on positive data from the phase 3 trial for chronic kidney disease

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Inizio

AstraZeneca AZ

Japan resumes AZ’s COVID-19 vaccine trial, but US study remains on hold

Trials have also resumed in the UK, India, South Africa and Brazil

- PMLiVE

Merck gets first approval for MET inhibitor tepotinib in Japan

First worldwide approval for MET inhibitor

- PMLiVE

BMS scores first oesophageal cancer nod for Opdivo in Japan

Approval in Japan comes before US okay

- PMLiVE

Astellas files new application for expanded use of roxadustat in Japan

Aims for use in anaemia associated with CKD in non-dialysis patients

- PMLiVE

Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

- PMLiVE

GSK files anaemia drug daprodustat in Japan, its first market

Around 3.5 million people in Japan could access the drug

Bayer symbol

Bayer roll-out of haemophilia drug Jivi gathers pace

Japan’s MHLW is next to approve the drug

Joel Colwell moves from Sanofi to J+D Consulting

He will support the firm’s senior team across their projects

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links